The long-held assumption that antibodies are exquisitely specific is being re-examined since 25% of monoclonal antibodies (MAbs) show polyspecificity and bind unintended targets.
This Fierce webinar brings together experts with experience in biotech, pharma, and the FDA to discuss the latest technologies and strategies to optimize IND safety data packages.
Topics to be discussed include:
Best practices to identify safe lead candidates early in development
Traditional approaches such as tissue cross-reactivity (TCR) studies and other in vitro toxicology assays
Emerging technologies including Integral Molecular’s Membrane Proteome Array (MPA), which tests the specificity of antibodies and CAR-T cells across an array of 6,000 native membrane proteins
